NICE update

Last update: 27.01.2012

For more information on BSR's involvement with NICE contact our senior policy officers Katy Lewis and Rachel Evans. Visit the National Institute of Health and Clinical Excellence (NICE) website.

---

NICE Clinical Guideline (CG79)

NICE has published its decision to not update the Rheumatoid Arthritis guideline (CG79) at this time.

Dr Chris Deighton (BSR President-Elect) remarked:

"BSR and other stakeholders felt there might be a case with new evidence to suggest that the use of anti-CCP should be broadened for diagnostic and prognostic purposes, and that it would be useful to have an update including the new EULAR/ACR classification criteria for early RA, but agreed with NICE that there was no major new evidence to lead to a change in recommendations. This decision wil be reviewed again in 2014. If the rheumatology community wants to improve the guidelines it will be necessary to generate the evidence in the meantime."

---

Quality Standards in RA

NICE is working hard on producing Quality Standards and will develop them for five musculoskeletal topics including RA. These will be incorporated into the first 150 topics of the Core Library in the National Outcomes Framework. BSR has been involved in suggesting to NICE key Quality Standards for RA that are based largely on the NICE RA guidelines. A formal process to develop these by NICE is expected in 2012.

View:
Top Ten Quality Standards for RA

---

Guideline Development Group Recruitment

The National Clinical Guidelines Centre (NCGC), hosted by the Royal College of Physicians and commissioned by NICE, to develop clinical guidelines and quality standards for osteoarthritis is recruiting health professionals to the guideline development group (GDG). The multi-disciplinary CDG will requires rheumatologists, orthopaedic surgeons, physiotherapists, nurses, GPs and others.

A commitment to the work of GDG of 24 months from 27 February 2012 with meetings every five to six weeks is required.

Closing date for applications is 9 January 2012.

To find out more:
Visit the NICE website's Get involved section
Email Vanessa Nunes, NCGC Project Manager or call her on 020 3075 1277.

---

Multiple Technology Appraisals

1. Rheumatoid Arthritis – drugs for treatment after failure of a TNF inhibitor

• NICE published an FAD on 25 June 2010
• BSR welcomes the ruling from NICE

2. Psoriatic arthritis - etanercept, infliximab and adalimumab (review)

• The FAD was released on 6 June 2010
• BSR welcomes this guidance

---

Single Technology Appraisals

1. Tocilizumab for Rheumatoid Arthritis

• NICE issued the FAD on 4 June 2010
• BSR welcomes the ruling from NICE

2. Certolizumab for Rheumatoid Arthritis

• Certolizumab has been approved by NICE and the guidance has been released

3. Denosumab for the prevention of osteoporotic fractures in postmenopausal women

• Denosumab has been approved by NICE and full guidance has been released

4. Golimumab for rheumatoid arthritis after failure of previous anti-rheumatic drugs

• NICE released the FAD on 6 May 2011
• BSR welcomes this ruling from NICE

5. Golimumab for ankylosing spondylitis

• NICE published full guidance in August 2011
• BSR welcomes this ruling from NICE

6. Golimumab for psoriatic arthritis

• NICE published full guidance in April 2011
• BSR welcomes this ruling from NICE

7. Abatacept for the treatment of rheumatoid arthritis after DMARDs failure

• NICE published full guidance in August 2011
• BSR welcomes this ruling from NICE

8. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus

• NICE issued the ACD in September 2001 not be recommending Belimumab
• BSR will be commenting on this ACD

9. Tocilizumab for Juvenile Idiopathic Arthritis

• Tocilizumab for JIA has been approved by NICE

10. Canakinumab for the treatment of acute gout flares and the delay of subsequent flares

• A scoping stage consultation has taken place

11. Pegloticase for hyperuricaemia in people with symptomatic gout refractory to conventional urate-lowering therapy

• BSR is taking part in the scoping stage consultation

12. Golimumab for rheumatoid arthritis (methotrexate-naive)

• NICE is unable to recommend the use in the NHS of golimumab for the for the treatment of methotrexate-naive rheumatoid arthritis because no evidence submission was received from the manufacturer or sponsor of the technology.

13. Tofacitinib for the treatment of moderate to severe rheumatoid arthritis

• BSR is taking part in the scoping stage consultation

  

---

Clinical Guidelines

1. Ankylosing Spondylitis

• BSR is supporting a call from National Ankylosing Spondylitis Society for there to be a national clinical guideline on ankylosing spondylitis
• NICE has agreed to produce guidleines on spondyloarthropathies (including ankylosing spondylitis) in the future. No date has been issued as yet.

2. Osteoarthritis

• NICE is updating the guidelines